# Blunt the inflammation that wakes sleeping cancer cells

Source: https://onco.cc/ideas/idea-bio2-il1-awakening-blockade/  
OnCo record `idea-bio2-il1-awakening-blockade` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inflammation from infection, injury or surgery can wake dormant cancer cells. Interleukin-1 beta drives that awakening in mouse models of breast cancer, and a cardiovascular trial of the interleukin-1 beta blocker canakinumab saw fewer lung cancers, so blocking it early might keep dormant cells asleep.

## Summary

Interleukin-1 beta from the bone marrow niche drives the exit of breast cancer cells from dormancy and metastatic outgrowth in mouse models, and a large cardiovascular trial of canakinumab reported an unexpected reduction in lung cancer incidence and mortality. Later lung cancer treatment trials of canakinumab in advanced disease were negative, which is consistent with awakening being an early, not late, event.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Interleukin-1 beta blockade in high-risk survivors reduces distant relapse rate, whereas the same drug has no effect in established metastatic disease.
- Rationale: Setting-dependence is the crux: an awakening inhibitor cannot shrink a tumour that is already growing. Testing prevention rather than treatment aligns the mechanism with the endpoint, and the CANTOS incidence signal is a human-level hint that the axis matters.
- Proposed test: A randomised trial in ctDNA-positive or clinically high-risk resected breast or lung cancer with relapse-free survival and ctDNA clearance as co-primary endpoints, powered for a modest effect and sized off the CANTOS incidence data.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022): https://doi.org/10.1056/NEJMoa2200075

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Late recurrence](https://onco.cc/terms/late-recurrence/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-il1-awakening-blockade.json